{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T17:42:13Z","timestamp":1789148533866,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T00:00:00Z","timestamp":1666137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T00:00:00Z","timestamp":1666137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["K08CA230319"],"award-info":[{"award-number":["K08CA230319"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Patients with multiple myeloma-bearing translocation t(11;14) have recently been shown to benefit from the apoptosis-inducing drug venetoclax; however, the drug lacks FDA approval in multiple myeloma thus far due to a potential safety signal in the overall patient population. Selinexor is an inhibitor of nuclear export that is FDA-approved for patients with multiple myeloma refractory to multiple lines of therapy. Here, we report that in four patients with multiple myeloma with t(11;14), the concomitant administration of venetoclax and selinexor was safe and associated with disease response. Moreover, the combination was synergistic in t(11;14) multiple myeloma cell lines and caused decreased levels of Cyclin D1 (which is overexpressed due to the\n                    <jats:italic>CCND1-IGH<\/jats:italic>\n                    fusion) when given in combination as compared to single agents. These data suggest that the combination of venetoclax and selinexor is effective and t(11;14) may serve as a therapeutic marker for response and target for future clinical trials.\n                  <\/jats:p>","DOI":"10.1038\/s41698-022-00315-2","type":"journal-article","created":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T08:04:09Z","timestamp":1666166649000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)"],"prefix":"10.1038","volume":"6","author":[{"given":"Nina","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1559-0974","authenticated-orcid":false,"given":"Sana","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tulasigeri M.","family":"Totiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Skye","family":"Montoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Pardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Pardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jumana","family":"Afaghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Affer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Jahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terrence","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Maura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dickran","family":"Kazandjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Bilbao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Landgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4407-6325","authenticated-orcid":false,"given":"Justin","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,19]]},"reference":[{"key":"315_CR1","doi-asserted-by":"publisher","first-page":"13931","DOI":"10.1073\/pnas.93.24.13931","volume":"93","author":"PL Bergsagel","year":"1996","unstructured":"Bergsagel, P. L. et al. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc. Natl Acad. Sci. USA 93, 13931\u201313936 (1996).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"315_CR2","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1182\/blood.V99.10.3735","volume":"99","author":"R Fonseca","year":"2002","unstructured":"Fonseca, R. et al. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood 99, 3735\u20133741 (2002).","journal-title":"Blood"},{"key":"315_CR3","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/leu.2017.204","volume":"32","author":"A Lakshman","year":"2018","unstructured":"Lakshman, A. et al. Natural history of t(11;14) multiple myeloma. Leukemia 32, 131\u2013138 (2018).","journal-title":"Leukemia"},{"key":"315_CR4","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1182\/blood-2003-11-3837","volume":"104","author":"K Specht","year":"2004","unstructured":"Specht, K. et al. Different mechanisms of cyclin D1 overexpression in multiple myeloma revealed by fluorescence in situ hybridization and quantitative analysis of mRNA levels. Blood 104, 1120\u20131126 (2004).","journal-title":"Blood"},{"key":"315_CR5","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/leu.2013.216","volume":"28","author":"C Touzeau","year":"2014","unstructured":"Touzeau, C. et al. The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia 28, 210\u2013212 (2014).","journal-title":"Leukemia"},{"key":"315_CR6","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1038\/s41375-018-0223-9","volume":"32","author":"C Touzeau","year":"2018","unstructured":"Touzeau, C., Maciag, P., Amiot, M. & Moreau, P. Targeting Bcl-2 for the treatment of multiple myeloma. Leukemia 32, 1899\u20131907 (2018).","journal-title":"Leukemia"},{"key":"315_CR7","doi-asserted-by":"publisher","first-page":"119047","DOI":"10.1016\/j.bbamcr.2021.119047","volume":"1868","author":"G Prado","year":"2021","unstructured":"Prado, G., Kaestner, C. L., Licht, J. D. & Bennett, R. L. Targeting epigenetic mechanisms to overcome venetoclax resistance. Biochim. Biophys. Acta Mol. Cell Res. 1868, 119047 (2021).","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"315_CR8","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","volume":"21","author":"SK Kumar","year":"2020","unstructured":"Kumar, S. K. et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 21, 1630\u20131642 (2020).","journal-title":"Lancet Oncol."},{"key":"315_CR9","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.clml.2018.03.003","volume":"18","author":"UH Gandhi","year":"2018","unstructured":"Gandhi, U. H. et al. Clinical implications of targeting XPO1-mediated nuclear export in multiple myeloma. Clin. Lymphoma Myeloma Leuk. 18, 335\u2013345 (2018).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"315_CR10","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.1101\/gad.854900","volume":"14","author":"JR Alt","year":"2000","unstructured":"Alt, J. R., Cleveland, J. L., Hannink, M. & Diehl, J. A. Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev. 14, 3102\u20133114 (2000).","journal-title":"Genes Dev."},{"key":"315_CR11","doi-asserted-by":"publisher","first-page":"56061","DOI":"10.1074\/jbc.M411910200","volume":"279","author":"S Benzeno","year":"2004","unstructured":"Benzeno, S. & Diehl, J. A. C-terminal sequences direct cyclin D1-CRM1 binding. J. Biol. Chem. 279, 56061\u201356066 (2004).","journal-title":"J. Biol. Chem."},{"key":"315_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-6-24","volume":"6","author":"JP Alao","year":"2007","unstructured":"Alao, J. P. The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol. Cancer 6, 24 (2007).","journal-title":"Mol. Cancer"},{"key":"315_CR13","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/nrc3090","volume":"11","author":"EA Musgrove","year":"2011","unstructured":"Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A. & Sutherland, R. L. Cyclin D as a therapeutic target in cancer. Nat. Rev. Cancer 11, 558\u2013572 (2011).","journal-title":"Nat. Rev. Cancer"},{"key":"315_CR14","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1007\/s00109-016-1475-3","volume":"94","author":"S Qie","year":"2016","unstructured":"Qie, S. & Diehl, J. A. Cyclin D1, cancer progression, and opportunities in cancer treatment. J. Mol. Med. 94, 1313\u20131326 (2016).","journal-title":"J. Mol. Med."},{"key":"315_CR15","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa1903455","volume":"381","author":"A Chari","year":"2019","unstructured":"Chari, A. et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N. Engl. J. Med. 381, 727\u2013738 (2019).","journal-title":"N. Engl. J. Med."},{"key":"315_CR16","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","volume":"396","author":"S Grosicki","year":"2020","unstructured":"Grosicki, S. et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet 396, 1563\u20131573 (2020).","journal-title":"Lancet"},{"key":"315_CR17","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","volume":"130","author":"S Kumar","year":"2017","unstructured":"Kumar, S. et al. Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma. Blood 130, 2401\u20132409 (2017).","journal-title":"Blood"},{"key":"315_CR18","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1158\/2159-8290.CD-19-0298","volume":"9","author":"J Taylor","year":"2019","unstructured":"Taylor, J. et al. Altered nuclear export signal recognition as a driver of oncogenesis. Cancer Discov. 9, 1452\u20131467 (2019).","journal-title":"Cancer Discov."},{"key":"315_CR19","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1182\/bloodadvances.2019000359","volume":"4","author":"MA Fischer","year":"2020","unstructured":"Fischer, M. A. et al. Venetoclax response is enhanced by selective inhibitor of nuclear export compounds in hematologic malignancies. Blood Adv. 4, 586\u2013598 (2020).","journal-title":"Blood Adv."},{"key":"315_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-33784-2","volume":"8","author":"E Shang","year":"2018","unstructured":"Shang, E. et al. Dual Inhibition of Bcl-2\/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems. Sci. Rep. 8, 15383 (2018).","journal-title":"Sci. Rep."},{"key":"315_CR21","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1158\/1535-7163.MCT-15-0730","volume":"15","author":"EA Punnoose","year":"2016","unstructured":"Punnoose, E. A. et al. Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models. Mol. Cancer Ther. 15, 1132\u20131144 (2016).","journal-title":"Mol. Cancer Ther."},{"key":"315_CR22","doi-asserted-by":"publisher","first-page":"12461","DOI":"10.1073\/pnas.1018941108","volume":"108","author":"E Beltran","year":"2011","unstructured":"Beltran, E. et al. A cyclin-D1 interaction with BAX underlies its oncogenic role and potential as a therapeutic target in mantle cell lymphoma. Proc. Natl Acad. Sci. USA 108, 12461\u201312466 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"315_CR23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/sj.cdd.4400770","volume":"8","author":"HM Lin","year":"2001","unstructured":"Lin, H. M., Lee, Y. J., Li, G., Pestell, R. G. & Kim, H. R. Bcl-2 induces cyclin D1 promoter activity in human breast epithelial cells independent of cell anchorage. Cell Death Differ. 8, 44\u201350 (2001).","journal-title":"Cell Death Differ."},{"key":"315_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2017.1283032","volume":"58","author":"P Bose","year":"2017","unstructured":"Bose, P., Gandhi, V. & Konopleva, M. Pathways and mechanisms of venetoclax resistance. Leuk. Lymphoma 58, 1\u201317 (2017).","journal-title":"Leuk. Lymphoma"},{"key":"315_CR25","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1182\/blood.2020007899","volume":"137","author":"VA Gupta","year":"2021","unstructured":"Gupta, V. A. et al. Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression. Blood 137, 3604\u20133615 (2021).","journal-title":"Blood"},{"key":"315_CR26","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/leu.2015.184","volume":"30","author":"C Touzeau","year":"2016","unstructured":"Touzeau, C. et al. BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics. Leukemia 30, 761\u2013764 (2016).","journal-title":"Leukemia"},{"key":"315_CR27","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/leu.2013.115","volume":"28","author":"YT Tai","year":"2014","unstructured":"Tai, Y. T. et al. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia 28, 155\u2013165 (2014).","journal-title":"Leukemia"},{"key":"315_CR28","doi-asserted-by":"publisher","first-page":"6099","DOI":"10.1111\/jcmm.13886","volume":"22","author":"DA Luedtke","year":"2018","unstructured":"Luedtke, D. A. et al. Inhibition of XPO1 enhances cell death induced by ABT-199 in acute myeloid leukaemia via Mcl-1. J. Cell Mol. Med. 22, 6099\u20136111 (2018).","journal-title":"J. Cell Mol. Med."},{"key":"315_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1627-9","volume":"10","author":"ZC Zhu","year":"2019","unstructured":"Zhu, Z. C., Liu, J. W., Yang, C., Zhao, M. & Xiong, Z. Q. XPO1 inhibitor KPT-330 synergizes with Bcl-xL inhibitor to induce cancer cell apoptosis by perturbing rRNA processing and Mcl-1 protein synthesis. Cell Death Dis. 10, 395 (2019).","journal-title":"Cell Death Dis."},{"key":"315_CR30","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar, S. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 17, e328\u2013e346 (2016).","journal-title":"Lancet Oncol."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-022-00315-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-022-00315-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-022-00315-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T08:15:35Z","timestamp":1666167335000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-022-00315-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,19]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["315"],"URL":"https:\/\/doi.org\/10.1038\/s41698-022-00315-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.08.01.22278282","asserted-by":"object"}]},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,19]]},"assertion":[{"value":"14 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.B.: AbbVie: membership on an entity\u2019s Board of Directors or advisory committees, speakers bureau; Novartis: consultancy, membership on an entity\u2019s Board of Directors or advisory committees. F.M.: OncLive: honoraria; Medscape: consultancy, honoraria. D.K.: Arcellx: honoraria, membership on an entity\u2019s Board of Directors or advisory committees; BMS: honoraria, membership on an entity\u2019s Board of Directors or advisory committees. O.L.: adaptive: honoraria; binding site: honoraria; BMS: honoraria; Cellectis: honoraria; Amgen: honoraria; Janssen: honoraria; Celgene: research funding; Janssen: other: IDMC; Janssen: research funding; Takeda: other: IDMC; Amgen: research funding; GSK: honoraria. J.T.: Karyopharm: honoraria.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"73"}}